Unilife (UNIFF) 8-K Unilife Corporation Announces Financial Results

Fiscal Year 2014 2

nd

Quarter Earnings Call

Exhibit 99.2

February 3, 2014

2

This

presentation contains forward looking statements under the safe harbor

provisions of the US securities laws. These forward-looking statements are based

on management’s beliefs and assumptions and on information currently available

to our management.

Our management believes that these forward-looking statements are reasonable

as and when made. However you should not place undue reliance on any such

forward looking statements as these are subject to risks and uncertainties.

Please

refer to our press releases and our SEC filings for more information regarding the

use of forward looking statements.

Cautionary Note Regarding Forward-Looking Statements

Introduction

to

Q214

Earnings

Call

3

Update on Signed Contracts

4

An

Expanding

Commercial

Pipeline

5

Multiple

customers

pursuing

multiple

products

across

multiple

platforms

Unifill

Finesse™

Unifill®

Unifill

Nexus™

Unifill

Allure™

Unifill

Select™

AutoMix

Presto™

EZMix

Genesis™

EZMix

Engage™

EZMix

Genesis™

Precision-Therapy™

Wearable Injector

Flex-Therapy ™

Wearable Injector

Ocu-ject ™

Depot-ject ™

Micro-ject ™

RITA™

auto-injector

LISA™

auto-injector

These products have not been evaluated by the FDA

Financial Data

•

Revenue growth of 411% compared to same period prior year

•

Period of sequential revenue growth quarter to quarter continues

•

Net loss per share (net and adjusted) is narrowing

•

Reducing SG&A, continued investment in R&D and operations

6

Three Months Ended

December 31,

Six Months Ended

December 31,

2013

2012

2013

2012

Revenues

$3.6MM

$0.7MM

$6.8MM

$1.4MM

Research & development

$7.8MM

$5.0MM

$14.2MM

$9.7MM

Selling, general & administrative

$6.7MM

$8.3MM

$13.2MM

$14.9MM

Net loss

$16.3MM

$14.6MM

$27.5MM

$27.1MM

Net loss per share –

diluted

$0.17

$0.19

$0.29

$0.35

Adjusted net loss

$8.3MM

$9.7MM

$15.4MM

$18.8MM

Adjusted net loss per share -

diluted

$0.08

$0.12

$0.16

$0.24

7

Existing clean

room space

Installation of

new clean

rooms

Doubling our cleanroom production space in York, PA

Building shareholder value

8

Sanofi

MedImmune

Hikma

Biodel

Novartis     Others

•

Commercial  supply

contracts

•

Customization and

clinical  supply contracts

•

Revenue from customers

Device sales, customization

programs, upfront fees

•

Debt financing

•

New clean rooms

•

Continued expansion

production capacities

•

Current platforms

•

New products

Questions